POTSDAM, GERMANY--(Marketwire - January 20, 2012) -
Signature Diagnostics /
Signature Diagnostics to Present Detector C 2.0 - A Blood Test for Early
Detection of Colorectal Cancer at the ASCO 2012 Gastrointestinal Cancer
Symposium in San Francisco
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Potsdam, Germany, January 20, 2012 - Signature Diagnostics AG announced
that the company was selected to present its improved test -Detector C
early detection of colorectal cancer (CRC) at the ASCO 2012
Cancer Symposium in San Francisco on January 19-21, 2012.
The paper, "Detector-c 2.0: A highly accurate blood-based IVD test for
detection of colorectal cancer with sensitivity and specificity over 90%."
be presented at the General Poster Session C on Cancers of the
Rectum, January 21, 2012, 8:00am-9:00am and 12:00-1:30pm.
Detector C 2.0 is an improved version of the Detector C test. It
panel of 1.000 RNA markers in whole blood. Detector C 2.0 is based on a
445 patients of which 291 patients were cases with confirmed CRC of all
stages, and 154 were healthy controls seeking a screening
underwent complete colonoscopy. Detector C 2.0 has a sensitivity of 91.6%
specificity of 94.8%. Sensitivity of high-grade intraepithelial
(high-grade adenoma) was 67%. Detector C 2.0 is based on a 3-times
patient set and shows an increase in sensitivity and specificity over
of 1.6% and 6.8%, respectively.
Signature Diagnostics AG is a molecular diagnostics company based in
Germany, focusing on the development and commercialization of novel
oncology diagnostic products for early detection (screening) and
cancer. The company has completed development of its first two
products for colorectal cancer screening ("Detector C/C+") and
("Predictor C"), which will be launched in 2012 in its own ISO 15189
service laboratory. Using its state-of-the-art technologies in tissue and
sample collection, molecular pathology, Xenopatient™ platform,
profiling, data mining, and biostatistics, the company collaborates
clinical, pharmaceutical, and diagnostic partners. Signature
sponsors and conducts large prospective, multicenter clinical trials with
than 33 primary care hospitals and several dozen colonoscopy centers in
to discover and validate biomarkers in oncology.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE